A Great New Ray of Hope for the Treatment of Malignant Ascites Fluid
Ascites is a disease in which fluid is accumulated in the abdominal cavity due to various conditions. It is more serious when it is caused by a cancer and then it is called malignant ascites. 10% of ascites patients come under this. Those having cancer of breast, liver, colon, pancreas, uterus, gastrointestinal tract and ovaries can suffer from malignant ascites. TD2 is performing a research in this which is funded by PharmaCyte Biotech, Inc. based at Silver Spring, Maryland, a clinical stage biotechnology company committed to develop treatments for cancer and diabetes with their unique live-cell encapsulation technology, named Cell-in-a-Box®. The research is designed to find out whether the pancreatic cancer treatment of PharmaCyte Biotech can decelerate the buildup of malignant ascite fluid. The said pancreatic cancer treatment is designed by combining low doses of ifosfamide, the cancer prodrug, and Cell-in-a-Box® capsules consisting of live cells which are capable of transforming ifosfamide into a cancer-destroying form.
In an animal study, mice were given an aggressive form of human ovarian cancer (ES-2) which generates sizeable amounts of malignant ascites fluid. The mice were split into 4 groups of 10 mice each. Group 1 was a control group, Group 2 consisted of mice treated with the pancreatic cancer treatment by PharmaCyte Biotech, Group 3 contained mice treated with a chemotherapy drug, cisplatin, generally used for the treatment of ovarian cancer and Group 4 contained mice treated with a combination of cisplatin and the pancreatic cancer treatment of PharmaCyte Biotech.
A follow-up study will be conducted by TD2 in the US wherein the same ES-2 model will be used. Here the mice will be split into 12 treatment groups of 10 each. This study is designed to define the parameters better that will be required to design a forthcoming Phase 1 clinical trial in human patients suffering from malignant ascites fluid buildup because of their abdominal cancers. The study is designed by Dr. Daniel D. Von Hoff, a pancreatic cancer expert, in cooperation with the researchers affiliated to PharmaCyte Biotech.
As told by PharmaCyte Biotech’s Chief Executive Officer Kenneth L. Waggoner, the company is looking forward to the outcomes of this extended preclinical research about the effectiveness of their pancreatic treatment decreasing the rate of malignant ascites fluid buildup in abdominal cavity. If it gets success, it will quickly give rise to a clinical trial in humans having abdominal tumors, like in this case of ovarian cancer, who undergo this very severe cancer-related malady.
It is expected by the researchers at PharmaCyte Biotech that their pancreatic cancer treatment will finally prove to be efficacious in reducing the rate of malignant ascites fluid accumulation, and thereby, lessen the number of withdrawals of the fluid that the patients need to endure for a certain period of time. They hope to help patients suffering from ascites fluid accumulation which is challenging for patients having an abdominal cancer, since it is painful and can create problems in breathing. It needs to remove the ascites fluid regularly when it reaches a certain level. This procedure is pretty uncomfortable and expensive.
About PharmaCyte Biotech
PharmaCyte Biotech (PMCB.OB) is a biotechnology company committed to developing and planning to commercialize therapies for cancer and diabetes with a base of an innovative Cell-in-a- Box® technology, a proprietary technology of encapsulation of cellulose-based live cells. This exclusive and patented technology will be used as a base on which therapies for many types of cancer, including complex, incurable pancreatic cancer and diabetes are being designed. The pancreatic cancer treatment by PharmaCyte Biotech includes low doses of the famous anticancer prodrug ifosfamide, along with encapsulated live cells, which transform ifosfamide into its potent or “cancer-destroying” form. These capsules are positioned in the vicinity of the cancer tumor as much as possible to enable maximum delivery of cancer-destroying drug at the site of cancer. This “targeted chemotherapy” has been proven significantly effective in the previous clinical trials.
PharmaCyte Biotech is also attempting towards improvement in the quality of life of patients with higher stage pancreatic cancer and taking treatments for other sorts of solid malignant tumors. Moreover, they are developing therapies for cancer, on the basis of chemical ingredients of the Cannabis plant, called cannabinoids. In these trials, the company is checking ways to acquire maximum benefits of Cell-in-a-Box® technology in maximizing the anticancer properties of cannabinoids, and at the same time minimizing or rather eliminating the unbearable side effects, that often come with cancer treatments. This offers PharmaCyte Biotech the rare chance of developing “green” ways to fight deadly disorders, like cancers of brain, pancreas and breast, which catch hold of hundreds of thousands of people throughout the world every year. Visit http://www.pharmacytebiotech.com/ for more information.